
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - Treatment of vitiligo has advanced significantly recently, although older therapies still retain an important place in the management of this therapeutically challenging disease, says Pearl E. Grimes, M.D.